WhatistheSymbol
Compugen Ltd trades in the stock market under the ticker symbol of CGEN. Search for the ticker of any public company above using the 'Get Ticker' search in red.

Who is Compugen Ltd?

Compugen Ltd. operates as a drug and diagnostic discovery company based on computer-based discovery capabilities to predict and select novel product candidates. Through in silico prediction and selection, the resulting novel molecules are synthesized and validated utilizing traditional in vitro and in vivo experimental procedures. The company provides these validated product candidates to pharmaceutical, biotech, and diagnostic companies under licensing and other commercialization arrangements. Its research and discovery efforts are focused primarily on therapeutic proteins and peptides, and monoclonal antibodies, and primarily in the fields of immunology and oncology. Its therapeutic peptide and protein related platforms include Protein Family Members Discovery Platform, Protein-Protein Interaction Blockers, GPCR Therapeutic Peptide Ligands, Disease-Associated Conformation Blockers, Intracellular Drug Delivery, Viral Peptides, and Splice Variant based Therapeutic Proteins. The company’s monoclonal antibody related platforms comprise Monoclonal Antibody Targets. Its other therapeutic and diagnostic platforms consist of Nucleic-Acid Disease Markers, Protein Disease Markers, Nucleic-Acid Preclinical Toxicity Markers, Non-SNP Drug Response Markers, and New Indications. Its therapeutic peptide and protein product candidates comprise CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-25017, a novel peptide antagonist of the Angiopoietin/Tie-2 pathway; CGEN-855, a peptide agonist of the FPRL1 GPCR receptor; CGEN-856 and CGEN-857, which are MAS GPCR peptide agonists; CGEN-25007, an antagonist of the gp96 protein; and CGEN-25009, a peptide of the LGR7 receptor. The company also offers monoclonal antibody target product candidates, including CGEN-671, a drug for multiple epithelial tumors; CGEN-928, a drug for multiple myeloma; and CGEN-15001T, a novel B7/CD28 family member. Compugen Ltd. was founded in 1993 and is based in Tel Aviv, Israel.

www.cgen.com
39 Employees
Last Reported Date: 03/14/12
Founded in 1993
Last $3.81 USD
Change Today -0.10 / -2.56%
Volume 22.1K
As of 8:10 PM 10/24/12 All times are local (Market data is delayed by at least 15 minutes).

compugen ltd (CGEN) Snapshot

Open
$3.91
Previous Close
$3.91
Day High
$3.92
Day Low
$3.74
52 Week High
02/2/12 - $6.47
52 Week Low
08/15/12 - $2.96
Market Cap
136.7M
Average Volume 10 Days
45.8K
EPS TTM
$-0.37
Shares Outstanding
35.9M
CGEN Does Not Pay Dividends
P/E TM
--
CGEN:US Historical Stock Quote
CGEN:US Advanced Stock Chart

Related News

No related news articles were found.

compugen ltd (CGEN) Related News

No Related News Found

compugen ltd (CGEN) Key Developments

Compugen Drug Candidate Demonstrates Attenuation of Autoimmunity and Reestablishment of Immune Balance

Compugen Ltd. announced that pre-clinical findings presented at the 3(rd) European Congress of Immunology provide additional support for the potential of CGEN-15001 to effectively treat autoimmune disease. Mode of action studies for CGEN-15001 demonstrated both the active suppression of pathogenic immune responses and the reestablishment of immune balance by increasing anti-inflammatory mediators and promoting inducible regulatory T cells (iTregs). Modulation of iTregs is considered an extremely promising approach for treatment of autoimmunity and cancer, and therefore has been the focus of intense industry and academic research in recent years. These results were included in a presentation focused on CGEN-15001 by Dr. Joseph R. Podojil, a Research Assistant Professor in the laboratory of Professor Stephen Miller at Northwestern University, at the 3(rd) European Congress of Immunology held last week in Glasgow, U.K. In his talk, Dr. Podojil presented data supporting multiple modes by which CGEN-15001 appears to mitigate aberrant immune function leading to autoimmunity. In addition to the data supporting its promotion of iTregs, which was disclosed for the first time at the congress, Dr. Podojil discussed CGEN-15001's previously reported ability to prevent autoreactive inflammatory immune cell infiltration to the central nervous system as well as its immunomodulatory activity, thereby both turning off pro-inflammatory immune cells and promoting immunoregulatory immune responses.

Compugen Ltd. Reports Unaudited Consolidated Cash Flow Results for the Six Months Ended June 30, 2012

Compugen Ltd. reported unaudited consolidated cash flow results for the six months ended June 30, 2012. For the six months, the company reported net cash used in operating activities of $5,543,000 against $3,877,000 a year ago. Purchase of property and equipment was $315,000 against $32,000 a year ago.

Compugen Ltd. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2012

Compugen Ltd. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2012. For the quarter, net loss was $626,000, after reflecting non-cash expense of $527,000 related to stock based compensation and non-cash financial income of $2.6 million related to the accounting for certain research and development funding arrangements, or $0.02 per basic and diluted share compared with net loss of $2.2 million, after reflecting non-cash expense of $1.7 million related to stock based compensation and non-cash financial income of $909,000 related to the research and development funding arrangements, or $0.06 per basic and diluted share for the corresponding quarter of 2011. Operating loss was $3 million against $3.4 million last year. For the six months, net loss was $4.7 million, after reflecting non-cash expense of $1.1 million related to stock based compensation and non-cash financial income of $1.3 million related to the research and development funding arrangements, or $0.13 per basic and diluted share compared with net loss of $4.1 million, including a non-cash expense of $2.0 million related to stock based compensation and non-cash financial income of $733,000 related to the research and development funding arrangements, or $0.12 per basic and diluted share for the same period in 2011. Operating loss was $6.1 million against $5.8 million last year.

Most Popular on

The Five Scariest Airports to Land a Plane
Apple’s Slim iMac Far Outshines the New iPad Mini
Convincing Women in China They're Too Hairy
How to Weaponize Office Supplies: Jörg Sprave
Apple's Big Show: Your IPad Just Became Totally Obsolete
More News
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CGEN:US $3.81 USD -0.10

CGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CGEN.
 

Industry Analysis

CGEN

Industry Average

Valuation CGEN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

  • Professor in Technology Management
    Santa Barbara, CA | University of California, Santa Barbara
    Posted: Oct 03
  • CLINICAL ASSISTANT PROFESSOR OF INTEGRATED MARKETING
    New York, NY | New York University
    Posted: Oct 01
  • Digital Traffic Coordinator
    New York, NY | Ted Conferences
    Posted: Sep 27
  • Program Officer for Direct to Consumer Initiatives
    Washington, DC | Institute For Reproductive Health
    Posted: Sep 27
Simply Hired

Sponsored Links

Compugen Discloses Discovery of Five Potential Cancer Targets for Antibody Drug Conjugate Therapy

[at noodls] - 11 December 2013 ADC target discovery is Company's second focused discovery program utilizing its in silico predictive discovery infrastructure Tel Aviv, Israel, - December 11, 2013 --- Compugen Ltd. ( ...

11 Dec 2014

Read More...
Compugen Ltd. Reports Third Quarter 2013 Financial Results

[at noodls] - 30 October 2013 Immune checkpoint related achievements include first collaboration agreement for cancer immunotherapy and experimental results supporting additional candidates Scientific Advisory Board ...

30 Oct 2014

Read More...
Compugen to Present Immune Checkpoint Related Research at Two Scientific Conferences

[at noodls] - Tel Aviv, July 24, 2014 - Compugen Ltd. ( NASDAQ: CGEN ) today announced that it will present aspects of its immune checkpoint related research at two upcoming scientific conferences. On August 11, John ...

24 Jul 2014

Read More...
Compugen jumps after announcing newly discovered proteins

14 Jul 2014

Read More...
Compugen Extends Discovery Capabilities to Additional Immunomodulatory Proteins

[at noodls] - Incorporation of algorithms modeling additional biological phenomena leads to predictive discovery of four potential immunomodulatory targets New candidates enter Company's Pipeline Program Tel Aviv, Israel, ...

14 Jul 2014

Read More...
7:05 am Compugen announced the extension of its predictive discovery capability to identify immunomodulatory proteins in addition to the B7/CD28-like proteins

14 Jul 2014

Read More...
Compugen Discloses Achievement of Milestone in Cancer Immunotherapy Collaboration with Bayer

[at noodls] - Tel Aviv, Israel - July 7, 2014 --- Compugen Ltd. (NASDAQ: CGEN) disclosed today that it has achieved the initial milestone in the cancer immunotherapy collaboration it entered last year with Bayer HealthCare ...

7 Jul 2014

Read More...
Compugen shares rise on news of positive cancer collaboration with Bayer

7 Jul 2014

Read More...
7:14 am Compugen discloses achievement of milestone in cancer immunotherapy collaboration with Bayer

7 Jul 2014

Read More...
Three Analyst Stocks With 50% to 100% Implied Upside

23 Jun 2014

Read More...
Subject Author Date
news... investment 8mm bonds2stocks 2012-09-17 23:12:54
cgen j.hallrun28 2012-09-17 23:12:31
cgen j.hallrun28 2012-09-17 23:12:15
not sure suejenseth 2012-09-17 23:11:59
Baize sabba41 2012-09-17 23:11:35
No agreements... zesceptic 2012-09-17 23:09:54
flatters to deceive j.hallrun28 2012-09-17 23:07:42
ried To Warn You!!! ibmwatcher 2012-09-17 23:06:45
Flatters to deceive gilliesman2002 2012-09-17 23:06:06
New discovery platforms daniellaidman 2012-09-17 23:05:51
Here Come The $2.00s??? ibmwatcher 2012-09-17 23:05:36
A better understanding of our science camster1952 2012-09-17 23:05:24
cgen gmuk13 2012-09-17 23:04:59
ABOUT PSTI elbit@rocketmail.com 2012-09-17 23:03:55
O.T. : PSTI daniellaidman 2012-09-17 23:03:24
Capable judgment johnnador 2012-09-17 23:01:25
So easily manipulated!! sydbiz2000 2012-09-17 23:00:25
CGEN lagrammy@sbcglobal.net 2012-09-17 22:59:57
CGEN lagrammy@sbcglobal.net 2012-09-17 22:59:39
new format acowoman 2012-09-17 22:59:19
September suejenseth 2012-09-17 22:58:56
Conference Sept 5-8 sethbru2 2012-09-17 22:58:12
$2.96!!! ibmwatcher 2012-09-17 22:57:50
CGEN -15001 sbh3117 2012-09-17 22:57:34
new Compugen blog entry johnnador 2012-09-17 22:57:03
  • 0
  • 4
  • 0

Get our Stock Market & Financial Investment news alerts in your inbox

Read our full disclaimer and privacy policy